

## API PRODUCT PORTFOLIO

PRODUCT	INDICATION	API MICRONIZED	CEP/DMF
<b>Arformoterol tartrate<sup>P</sup> polymorph A and D</b>	COPD		US-CN DMF
<b>Formoterol fumarate</b>	Asthma and COPD	√	CEP / US-JP-KR-CN DMF
<b>Glycopyrronium bromide<sup>P</sup></b>	COPD	√	CEP / US-CN DMF
<b>Indacaterol maleate<sup>P</sup></b>	Asthma and COPD	√	EU/US DMF
<b>Salmeterol xinafoate<sup>P</sup></b>	Asthma and COPD	√	CEP / US-CN-KR DMF
<b>Tiotropium Bromide</b>	COPD	√	CEP / US-CN DMF

## API PRODUCT PIPELINE

PRODUCT	INDICATION	SAMPLES	TECHNICAL PACKAGE	VALIDATION BATCH	DMF
<b>Abediterol</b>	Asthma and COPD			2023	2023
<b>Aclidinium bromide</b>	COPD	√	√	Q3 2020	Q1 2021
<b>Batefenterol</b>	COPD			2023	2024
<b>Olodaterol<sup>P</sup></b>	COPD	√	√	Q3 2020	Q1 2022
<b>Revefenacin</b>	COPD			Q2 2021	Q4 2021
<b>Umeclidinium bromide</b>	COPD	√	√	Q4 2020	Q3 2021
<b>Vilanterol</b>	Asthma and COPD	√	√	√	Q2 2020

CEP = Products with Certificate of Suitability / P = Patent applications/granted patents owned by Neuraxpharm

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.